Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

US biotech major Amgen, a late comer to the growing obesity treatment space, released new data showing that its MariTide ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

Obesity late-comer Amgen announced full results from Part 1 of the Phase II study of MariTide (maridebart cafraglutide, ...